https://www.selleckchem.com/products/vb124.html
Aims To compare intravitreal ranibizumab as monotherapy or in combination with panretinal photocoagulation (PRP) in patients with proliferative diabetic retinopathy (PDR) and coexistent diabetic macular edema (DME) in a long-term follow-up of 24 months. Methods Participants in this prospective study were 47 patients with PDR and concurrent DME, who were randomized at baseline into two groups (i) the "ranibizumab alone" group (n = 23), which was treated with at least 3 intravitreal ranibizumab injections as a loading phase, and (ii) the "c
Like
Comment
Share
